Cancer-Fighting T-Cell therapy trial for GI cancers withdrawn before start
NCT ID NCT06690281
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to receive the cell therapy plus chemotherapy or to receive no treatment. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modified T-cells (KRAS or TP53-targeting T-cell receptor transduced peripheral blood lymphocytes)
What this could lead to
If successful, this approach could help prevent gastrointestinal cancers from returning after standard treatment in people with specific genetic mutations.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. The therapy involves intensive chemotherapy and hospitalization, with risks of severe side effects from the cell infusion and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States